Menu

“Father of Modern Hematology” Dies

Australian researcher Donald Metcalf, whose discoveries transformed cancer treatment, has passed away at age 85.

Dec 17, 2014
Molly Sharlach

WEHIDonald Metcalf, whose studies of blood cell formation led to improved outcomes for cancer patients, died this week (December 15) at the age of 85. He was diagnosed with metastatic pancreatic cancer in August.

Metcalf earned a medical degree at the University of Sydney in 1953, and spent 60 years as an investigator at the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, where he characterized colony stimulating factors (CSFs), which regulate the production of white blood cells. His work on CSFs led to the widespread clinical use of these growth factors to restore immune function in cancer patients undergoing chemotherapy. 

“CSFs are now standard treatment and every year the number of people alive because of Don’s work grows,” wrote WEHI Director Douglas Hilton in a tribute to Metcalf. “There can be no greater legacy for a medical researcher.”

“When he was diagnosed with cancer in August . . . the two things he wanted to do was spend as much time as possible with his wife, Jo, and his daughters, but also to continue to do his research,” Hilton told the Australia’s ABC. “His solution was to have his microscope, which was his valued possession at work, shipped home and it sat on his dining room table . . . he’d be able to sneak in some experiments in the afternoon and then spend the time with his wife, so really that kept going until about a month ago.”

Metcalf’s research has also impacted the fields of blood stem cell transplantation and rheumatoid arthritis treatment. He received several awards during his career, including the Albert Lasker Clinical Medical Research Award in 1993.

He is survived by his wife, four daughters, and six grandchildren.

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.
Corning Introduces New 1536-well Spheroid Microplate
Corning Introduces New 1536-well Spheroid Microplate
High-throughput spheroid microplate benefits cancer research, drug screening